Table 3.
The antimicrobial susceptibility testing of A. baumannii isolates to 15 antibiotics over the past 12 years.
| Antibiotics |
2008–2009
(n = 10) |
2010–2011
(n = 46) |
2012–2013
(n = 42) |
2014
(n = 41) |
2015–2016
(n = 55) |
2017
(n = 15) |
2018
(n = 27) |
2019
(n = 59) |
|---|---|---|---|---|---|---|---|---|
| Susceptibility | Susceptibility | Susceptibility | Susceptibility | Susceptibility | Susceptibility | Susceptibility | Susceptibility | |
| [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | |
| Amikacin | 0 | 5 (10.9%) | 22 (53.4%) | 2 (8.0%) | 1 (1.8%) | 2 (13.3%) | 1 (3.7%) | 4 (6.7%) |
| Gentamicin | 0 | 2 (4.3%) | 0 | 2 (8.0%) | 1 (1.8%) | 0 | 1 (3.7%) | 4 (6.7%) |
| Tobramycin | 0 | 5 (10.9%) | 22 (53.4%) | 2 (8.0%) | 1 (1.8%) | 1 (6.7%) | 1 (3.7%) | 4 (6.7%) |
| Ceftazidime | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ceftriaxone | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cefepime | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Piperacillin/tazobactam | 0 | 0 | 0 | 1 (4.0%) | 0 | 0 | 0 | 0 |
| Cefoperazone/sulbactam | 0 | 6 (13.0%) | 1 (4.8%) | 1 (4.0%) | 3 (5.5%) | 0 | 0 | 0 |
| Meropenem | 0 | 0 | 1 (2.4%) | 1 (4.0%) | 0 | 0 | 0 | 0 |
| Imipenem | 0 | 0 | 1 (2.4%) | 1 (4.0%) | 0 | 0 | 0 | 0 |
| Levofloxacin | 0 | 0 | 0 | 2 (8.0%) | 0 | 5 (33.3%) | 0 | 0 |
| Ciprofloxacin | 0 | 0 | 0 | 2 (8.0%) | 0 | 0 | 0 | 0 |
| Cotrimoxazole | 0 | 1 (2.2%) | 0 | 0 | 2 (3.6%) | 0 | 8 (29.6%) | 2 (3.4%) |
| Tigecycline | 10 (100%) | 28 (60.9%) | 25 (59.5%) | 41 (100%) | 41 (74.5%) | 15 (100%) | 27 (100%) | 59 (100%) |
| Polymyxin E | 10 (100%) | 46 (100%) | 42 (100%) | 41 (100%) | 55 (100%) | 15 (100%) | 27 (100%) | 59 (100%) |